Alemtuzumab and stem cell transplantation versus non-induction therapies in multiple sclerosis


  • There is an increased incidence of thyroid disease with alemtuzumab (ATB), and of infection with autologous hematopoietic stem cell transplantation (AHSCT) compared with non-induction therapies in the treatment of patients with multiple sclerosis (MS).

Why this matters

  • In Sweden, ATB (monoclonal antibody, induces depletion and repopulation of CD52+ cells) and AHSCT are mainly used for aggressive relapsing MS; however, their widespread use is limited by concerns and uncertainty around their safety compared with other MS therapies.

  • The association of increased thyroid disease and infection risk with ATB and AHSCT complements current therapeutic knowledge, allowing clinicians and patients with MS to make more informed treatment decisions; and provides a basis for further study.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.